Enanta: JMP Securities Raises PT to $25 from $24, Maintains Market Outperform Rating

Enanta: JMP Securities Raises PT to $25 from $24, Maintains Market Outperform Rating

Enanta Pharmaceuticals Inc. (ENTA) has seen a significant boost in its stock price following a positive earnings report and an updated price target from JMP Securities. The Watertown, Massachusetts-based biotechnology company reported a quarterly loss of $0.85 per share, which was a surprise improvement of +32.00% compared to the Zacks Consensus Estimate of $1.25 per share [1].

JMP Securities has raised its price target for Enanta Pharmaceuticals to $25 from $24, while maintaining its Market Outperform rating. This decision was likely influenced by the company's recent earnings performance, which has consistently beaten analyst estimates. Over the last four quarters, Enanta Pharmaceuticals has surpassed consensus EPS estimates two times [1].

The company's revenues for the quarter ended June 2025 were $18.31 million, surpassing the Zacks Consensus Estimate by 21.29% [1]. This quarterly report represents a 20% gain for Enanta Pharmaceuticals shares since the beginning of the year, outperforming the S&P 500's gain of 8.6% [1].

Analysts are cautiously optimistic about Enanta Pharmaceuticals' future prospects. The current consensus EPS estimate for the coming quarter is -$1.21 on $15.35 million in revenues, and -$4.33 on $62.35 million in revenues for the current fiscal year [1]. The company's earnings outlook will be a critical factor in determining its stock price performance in the near future.

Enanta Pharmaceuticals' industry, Medical - Biomedical and Genetics, is currently ranked in the bottom 41% of the 250 plus Zacks industries. However, the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [1]. This suggests that while the industry faces challenges, there are opportunities for companies like Enanta Pharmaceuticals to excel.

In terms of the Zacks Rank, Enanta Pharmaceuticals is currently rated #3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [1]. This rating is subject to change based on future earnings reports and estimate revisions.

References:
[1] https://finance.yahoo.com/news/enanta-pharmaceuticals-enta-reports-q3-225505580.html